Description: Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company also offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. As of March 31, 2022, it operated in 252 home health agencies and 99 hospice agencies across 34 states. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was incorporated in 2014 and is headquartered in Dallas, Texas. As of July 1, 2022, Enhabit, Inc. operates as a standalone company.
Home Page: www.ehab.com
EHAB Technical Analysis
6688 N. Central Expressway
Dallas,
TX
75206
United States
Phone:
214-239-6500
Officers
| Name | Title |
|---|---|
| Ms. Barbara Ann Jacobsmeyer B.S., M.A., P.T. | Pres, CEO & Director |
| Ms. Crissy Buchanan Carlisle | Chief Financial Officer |
| Mr. Dan Peoples | Exec. VP of Sales & Marketing |
| Ms. Tanya R. Marion | Chief HR Officer |
| Ms. Julie D. Jolley B.S.N., R.N. | Exec. VP of Home Health & Hospice Operations |
| Ms. Jeanne Kalvaitis B.S.N., R.N. | Exec. VP of Hospice Operations |
| Mr. Bud Langham M.B.A., P.T. | Exec. VP of Clinical Excellence & Strategy |
Exchange: NYSE
Country: US
Currency: US Dollar ($)
| Forward PE: | 13.21 |
|---|---|
| Trailing PE: | 7.5 |
| Price-to-Book MRQ: | 0.8327 |
| Price-to-Sales TTM: | 0.6408 |
| IPO Date: | 2022-07-01 |
| Fiscal Year End: | December |
| Full Time Employees: | 10000 |